Inhaler

Dec 22, 1997 - Novartis AG

Latest Novartis AG Patents:

5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
Solid support
Antibody molecules to LAG-3 and uses thereof
Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide

Description

FIG. 1 front and side perspective view;

FIG. 2 side perspective view;

FIG. 3 bottom perspective view; and,

FIG. 4 top perspective view.

Referenced Cited

U.S. Patent Documents

D348928	July 19, 1994	Ashley et al.
D397435	August 25, 1998	Naumann
3991761	November 16, 1976	Cocozza

Patent History

Patent number: D410541
Type: Grant
Filed: Dec 22, 1997
Date of Patent: Jun 1, 1999
Assignee: Novartis AG (Basel)
Inventor: Claude Moulin (Rheinfelden)
Primary Examiner: Stella Reid
Assistant Examiner: I Simmons
Attorneys: Stephen G. Kalinchak, William K. Wissing
Application Number: 0/80,996

Classifications

Current U.S. Class: Respirator, Vaporizer, Or Inhalation Tube (4) (D24/110)
International Classification: 2404;